Avacincaptad Pegol Demonstrates Sustained Benefit in Slowing Geographic Atrophy Progression
Orlando – Three-year data from the GATHER2 open-label extension trial reveal avacincaptad pegol (ACP) continues to demonstrate efficacy in slowing the growth of geographic atrophy (GA) lesions, a leading cause of vision loss in advanced age-related macular degeneration (AMD). The treatment was well-tolerated, with no new safety signals or cases of retinal vasculitis reported.
GA affects millions worldwide,progressively destroying central vision and substantially impacting quality of life. Currently, there are limited treatment options available. These latest findings build upon previous positive results, offering renewed hope for individuals with GA and potentially delaying the need for more invasive interventions. The data, presented at the American Academy of Ophthalmology meeting, suggest ACP could become a crucial tool in preserving vision for those at risk of advanced AMD.
“What this study shows is that early treatment with ACP demonstrated increased efficacy in slowing GA lesion growth over time,” saeid led investigator Amina Khanani, MD.
The GATHER2 extension trial provides long-term follow-up data on patients initially enrolled in the pivotal GATHER1 and GATHER2 trials. ACP is a C5 complement inhibitor designed to target the underlying cause of GA progression.
Source: Khanani AM. Avacincaptad pegol for GA: 3-year results from the GATHER2 open-label extension trial. Presented at: American Academy of Ophthalmology meeting; Oct. 17-20, 2025; Orlando.
Disclosure: Khanani reports consulting for Astellas.
